Ultrasis Plc Regulatory News (ULT)

Ultrasis plc

("Ultrasis" or the "Company")

Financing update

Further to the announcement of 7 October 2014, the Company announces that it has entered into further discussions with Mr Paul Bell, a substantial shareholder in the Company.

The Company and Mr Bell are currently considering a number of options. In the event that these discussions did result in an agreement for Mr Bell to provide further funding over and above the current loan facility it is likely that any such funding would result in shares in the Company being issued at a discount to the current share price. If this was to happen, it is the intention that other ordinary shareholders in the Company would be able to participate on comparable terms in respect of any equity investment.

A refinancing is still far from certain and any significant equity investment will require the consent of both The Panel on Takeovers and Mergers and shareholders independent of Mr Bell.

Therefore, whilst there can be no guarantee as to a successful conclusion to these ongoing discussions, the Company has, with Mr Bell's agreement, postponed posting a circular to shareholders seeking cancellation of the Company's shares to trading on AIM.

A further announcement will be made in due course and in the meantime Mr Bell continues to provide working capital to the Company under the terms of the existing loan arrangements (the "Current Facilities"). It remains the case that Mr Bell's consent is required in relation to each drawdown under the Current Facilities on an ongoing basis for the reasons set out in the announcement dated 7 October 2014.

For all enquiries relating to Ultrasis please contact:

Notes to Editors:

Ultrasis is a healthcare company with core expertise in health, psychology, software development and programme management. We deliver a range of healthcare products to the consumer, the NHS, the corporate sector and other healthcare providers in the UK and Internationally. Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is still the world leader in this field.